Developing a Vaccine for Lewy Body Dementia
Official title: IND enabling CMC/safety/toxicology studies, submission of IND and pilot Phase 1 clinical trial with PV-1950R vaccine for Lewy Body Dementia (LBD)
Funded at Institute for Molecular Medicine · NIH-11103129 · Data updated 2026-11-12
This project is developing a new vaccine called PV-1950R to help people with Lewy Body Dementia.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Institute for Molecular Medicine NIH-funded |
| Lab location | 1 site (Huntington Beach, United States) |
| Project start | June 5, 2024 |
| Project end | May 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $1,849,047 |
| NIH project number | 5U01AG084528-02 |
| Project ID | NIH-11103129 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients diagnosed with Lewy Body Dementia, or potentially those with early signs like rapid eye movement sleep behavior disorder, may be ideal candidates for future participation.
✕Less likely to help
Individuals without Lewy Body Dementia or related conditions would not receive direct benefit from this specific vaccine.
What this research studies
Lewy Body Dementia (LBD) is a severe form of dementia affecting many people, and currently, there are no approved treatments. This project focuses on creating a vaccine, PV-1950R, designed to target a specific protein called alpha-synuclein (αSyn) that builds up in the brains of individuals with LBD. The goal is to prevent or slow down the accumulation of this protein, which is believed to cause the disease's progression. This work involves preparing the vaccine for human use and conducting a small initial clinical trial to test its safety.
Why it matters
Potential benefit: If successful, this vaccine could offer the first approved treatment for Lewy Body Dementia, potentially slowing its progression or preventing its onset.
How similar studies have gone: Immunotherapy is a promising approach being explored for neurodegenerative diseases, though this specific vaccine is in early development.
Where this research is happening
-
Institute for Molecular Medicine
Huntington Beach, United States Active
Researchers
- Principal investigator: Agadjanyan, Michael G — Institute for Molecular Medicine
- Study coordinator: Agadjanyan, Michael G
Related research
Other NIH-funded projects on the same topics.
-
Investigating how DNA damage and repair mechanisms are altered in ALS and frontotemporal dementia.
This study is looking at how problems with DNA repair might contribute to conditions like ALS and frontotemporal dementia, and it’s testing ways to fix these issues in cells from patients to help develop new treatments.
-
Synthetic protein mimetics to treat Lewy Body Dementia
A new therapeutic approach using engineered protein-like molecules to block the harmful protein clumps that cause Lewy Body Dementia.
-
Dementia care staff study: adapting a US survey for use in many countries
A study is adapting and testing a survey for dementia care workers in the US, Brazil, Switzerland, and Ghana to help understand why workers stay in their jobs and how to improve care.
-
Dementia care staff study: adapting a survey for use in many countries
A multinational study will adapt and test a U.S. dementia-care worker survey in Brazil, Switzerland, and Ghana to help understand why staff stay in or leave long-term care settings.
-
Study of Dementia Care Staff in 4 Countries: Adapting Caregiver Surveys Across Cultures
A multinational project will adapt and test a dementia care worker survey so researchers can compare care environments across the US, Brazil, Switzerland, and Ghana.
-
New biomarkers to distinguish LATE from Alzheimer’s disease in dementia
A study to develop blood and CSF tests that can tell apart LATE from Alzheimer’s disease in people with dementia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.